IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Biosciences (Nasdaq: IDYA) closed an underwritten public offering of 7,222,225 common shares at $27.00 and pre-funded warrants for 5,555,576 shares at $26.9999 per warrant.

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) closed an underwritten public offering of 7,222,225 common shares at $27.00 and pre-funded warrants for 5,555,576 shares at $26.9999 per warrant. Underwriters fully exercised their option for 1,666,669 extra shares, generating approximately $345 million in gross proceeds.

Positive

• Gross proceeds of approximately $345 million from the offering
• Underwriters fully exercised option for 1,666,669 additional shares
• Financing completed under an effective Form S-3 shelf registration

Negative

• New common shares and pre-funded warrants may dilute existing shareholders' ownership
• Underwriting discounts, commissions and expenses will reduce net proceeds below $345 million

Argus Jun 11 session

+4.49% close to close 1.3x rel. volume Open Argus

Details

News Market Reaction – IDYA

On Jun 11, the first trading day after this news, IDYA closed 4.49% above the previous close.

Data tracked by StockTitan Argus for the Jun 11 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 5,555,576 shares of common stock at a public offering price of $26.9999 per pre-funded warrant, before underwriting discounts and commissions. This includes the exercise in full by the underwriters of their option to purchase up to an additional 1,666,669 shares of common stock in the offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, were approximately $345.0 million.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

The public offering was made by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities, by mail at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; UBS Investment Bank, by mail at UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, Attention: Equity Syndicate, or by email at ol-prospectus-request@ubs.com; or Cantor, by mail at Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302797230.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEAYA (Nasdaq: IDYA) announce on June 10, 2026 about its public offering?

IDEAYA announced the closing of its underwritten public offering of common stock and pre-funded warrants. According to IDEAYA, the transaction included both new shares and pre-funded warrants, with underwriters exercising their option to purchase additional common shares in full.

How much capital did IDEAYA (IDYA) raise in its June 2026 public offering?

IDEAYA raised gross proceeds of approximately $345 million from the offering. According to IDEAYA, this total is before underwriting discounts, commissions and other offering expenses, so the final net proceeds available to the company will be lower than $345 million.

How many IDEAYA (IDYA) shares and pre-funded warrants were sold in the June 2026 offering?

IDEAYA sold 7,222,225 shares of common stock and pre-funded warrants for 5,555,576 shares. According to IDEAYA, this figure includes 1,666,669 additional common shares issued after underwriters fully exercised their option to purchase extra stock in the deal.

At what price were IDEAYA (IDYA) shares and pre-funded warrants offered in June 2026?

IDEAYA priced its common stock at $27.00 per share and pre-funded warrants at $26.9999 each. According to IDEAYA, these prices are stated before deducting any underwriting discounts and commissions associated with the public offering transaction.

Did underwriters exercise their option in IDEAYA’s June 2026 stock offering (IDYA)?

Yes, underwriters exercised their option in full to buy additional IDEAYA common shares. According to IDEAYA, the option covered up to 1,666,669 extra shares, all of which were purchased as part of the completed public offering.

How was IDEAYA’s June 2026 public offering (IDYA) registered with the SEC?

IDEAYA conducted the offering under an automatically effective shelf registration statement on Form S-3. According to IDEAYA, a final prospectus supplement and accompanying prospectus were filed with the SEC and are available on the SEC’s public website.

Where can investors access the IDEAYA (IDYA) June 2026 offering prospectus?

Investors can access the final prospectus supplement and prospectus on the SEC’s website. According to IDEAYA, copies can also be requested from J.P. Morgan, Jefferies, TD Securities, UBS Investment Bank or Cantor through their listed mail, email or telephone contacts.